This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|December 3, 2012
Lilly Releases Corporate Responsibility Update
Author(s)Amy Ritter, PhD
Eli Lilly released its annual report containing updates on progress and new initiatives in corporate responsibility.
Advertisement
Eli Lilly released its annual report containing updates on progress and new initiatives in corporate responsibility. The
Included in the report are highlights indicating that Lilly:
- Gave more than $590 million in charitable contributions in 2011, including cash, products, and other in-kind donations, and also including contributions made through the company's patient assistance programs
- Introduced The Lilly Global Health Innovation Campaign. The campaign encompassses two corporate responsibility programs, the Lilly NCD Partnership and the Lilly MDR-TB Partnership, aimed at improving health for people in need in developing countries
- Received a perfect score of 100 on the Human Rights Campaign's "Best Places to Work: Corporate Equality Index" in 2011
- Selected 200 employees to volunteer two weeks each, on company time, in countries where people lack resources or access to quality healthcare
- Reduced serious injury and lost-time injury rates each by 50% since 2007
- Decreased water intake by more than 25% and waste to landfill by 40% compared with 2007
- Improved energy efficiency by more than 15% compared with 2007, and reduced corresponding greenhouse gas emissions by more than 15%.
"Increasingly, we are integrating the concept of 'shared value' into the way we operate," said John C. Lechleiter, PhD, Lilly chairman, president and chief executive officer in a company
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Advertisement
Advertisement